TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) – Stock analysts at HC Wainwright cut their Q2 2023 earnings estimates for TScan Therapeutics in a research note issued to investors on Thursday, May 11th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.04) per share for the quarter, down from […]